NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Enrollment continues in the Phase 2b/3 clinical trial evaluating NRX-101 in Suicidal Treatment-Resistant Bipolar Depression; data expected in 4Q 2023 National educational campaign launched to further accelerate enrollment in Breakthrough Therapy Designation meeting for NRX-101 in Suicidal…

Leave a Reply

Your email address will not be published. Required fields are marked *